Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    4
ATC Name B/G Ingredients Dosage Form Price
L03AA02 NEOGRASTIM 30 BioTech Filgrastim - 300mcg/ml 300mcg/ml Injectable solution 1,970,969 L.L
L03AA02 NEUTROMAX BioTech Filgrastim - 300mcg/ml 300mcg/ml Injectable solution 2,553,301 L.L
N03AF01 NEUROTOP RETARD G Carbamazepine - 300mg 300mg Tablet, prolonged release 931,283 L.L
N03AX12 NEUROPLEX G Gabapentin - 300mg 300mg Capsule 1,107,326 L.L
L01CA04 NAVELBINE B Vinorelbine (ditartrate) - 30mg 30mg Capsule, soft gelatin 6,072,824 L.L
C08CA05 NIFELAT 30 LA G Nifedipine - 30mg 30mg Tablet, prolonged release 1,007,882 L.L
C08CA06 NIMOTOP B Nimodipine - 30mg 30mg Tablet, film coated 581,884 L.L
L03AA02 NIVESTIM BioTech Filgrastim - 30MIU/0.5ml 30MIU/0.5ml Injectable solution 17,110,745 L.L
H01BA02 NICTUR G Desmopressin acetate - 360mcg/ml 360mcg/ml Solution 5,270,550 L.L
L01XG03 NINLARO B Ixazomib - 3mg 3mg Capsule, hard 348,420,676 L.L
S01AE02 NAFLOX G Norfloxacin - 3mg/ml 3mg/ml Drops 370,901 L.L
N03AX12 NEUROPLEX G Gabapentin - 400mg 400mg Capsule 1,290,089 L.L
J05AP08 NUCLEOBUVIR G Sofosbuvir - 400mg 400mg Tablet, film coated 50,670,440 L.L
M01AE01 NORFEN 400 G Ibuprofen - 400mg 400mg Tablet, film coated 173,356 L.L
J01MA06 NOROXIN B Norfloxacin - 400mg 400mg Tablet, film-scored 574,653 L.L
H02AB04 NEPHARED G Methylprednisolone sodium succinate - 40mg 40mg Injectable powder for solution 188,138 L.L
A02BC05 NEXIUM B Esomeprazole (magnesium trihydrate) - 40mg 40mg Tablet, enteric coated 1,138,235 L.L
A02BC05 NEXIUM B Esomeprazole (magnesium trihydrate) - 40mg 40mg Tablet, enteric coated 1,138,235 L.L
A02BC05 NEXIUM B Esomeprazole sodium - 40mg 40mg Injectable powder for solution 5,254,424 L.L
A03AB06 NOSPAZM G Otilonium bromide - 40mg 40mg Tablet, film coated 282,207 L.L
L01XG03 NINLARO B Ixazomib - 4mg 4mg Capsule, hard 388,991,058 L.L
A04AA01 NOZAMET G Ondansetron - 4mg 4mg Film, orodispersible 3,234,181 L.L
N04BC09 NEUPRO B Rotigotine - 4mg/24h 4mg/24h Patch 7,292,823 L.L
C01CA03 NORADRENALINE HIKMA G Noradrenaline bitartrate - 4mg/4ml 4mg/4ml Injectable solution 1,279,338 L.L
A04AA01 NAUSETRON G Ondansetron - 4mg/5ml 4mg/5ml Solution 958,608 L.L
A04AA01 NAUSETRON G Ondansetron - 4mg/5ml 4mg/5ml Solution 802,466 L.L
B02BD02 NOVOEIGHT BioTech Turoctocog Alfa - 500IU 500IU Injectable powder for solution+diluent 29,783,973 L.L
B02BD02 NUWIQ BioTech Coagulation Factor VIII recombinant, human (Simoctogog alfa) - 500IU 500IU Injectable powder for solution+diluent 45,612,427 L.L
M01AE02 NOPAIN DS G Naproxen (sodium) - 500mg 500mg Tablet, film coated 235,172 L.L
N02BE01 NOMAL G Paracetamol - 500mg 500mg Tablet 305,884 L.L
    4
Sitemap
© Copyrights reserved to Ministry of Public Health 2025